Can I Take Vitamin D with Rezdiffra (Resmetirom)?

What Is Resmetirom and Why Does It Matter for Liver Disease?

Resmetirom (Rezdiffra) is the first drug the FDA approved specifically for MASH, doing so on March 14, 2024. It targets the thyroid hormone receptor beta isoform that is expressed primarily in the liver, which lets the drug lower hepatic lipid synthesis and reduce liver fibrosis without the cardiac side effects that come from activating thyroid receptor alpha in heart tissue.

How Resmetirom Works in the Liver

Resmetirom acts as a selective THR-β agonist. In the MAESTRO-NASH trial (N=966), resmetirom 100 mg produced MASH resolution in 25.9% of participants versus 14.2% on placebo (P<0.001) at 52 weeks, and fibrosis improvement by at least one stage in 26.0% versus 14.2% (P<0.001) [1]. Those numbers gave regulators enough confidence to grant full approval.

The CYP Enzyme Profile

Resmetirom is metabolized primarily by CYP2C8 and, to a lesser extent, CYP3A4 [2]. Vitamin D (cholecalciferol) is hydroxylated first in the liver by CYP2R1 and CYP27A1, then in the kidney by CYP27B1. These pathways do not overlap with CYP2C8. That divergence in metabolic routing is the core reason no pharmacokinetic interaction is expected between the two agents.

P-glycoprotein and OATP Transporters

The Rezdiffra prescribing information flags resmetirom as a substrate of OATP1B1 and OATP1B3 [2]. Vitamin D and its metabolites are not known inhibitors or inducers of those transporters at physiologic or supplemental concentrations, according to the FDA drug interaction guidance framework [3]. So transporter-level interference is also not anticipated.

Why Vitamin D Deficiency Is So Common in MASH

This matters clinically, because the question of whether to supplement is almost always yes for a MASH patient. Vitamin D deficiency in MASH is not incidental.

Liver-Specific Conversion Steps

The liver performs the first hydroxylation step converting cholecalciferol to 25-hydroxyvitamin D (25-OH D). A fatty, inflamed, fibrotic liver does this less efficiently. A 2013 systematic review by Eliades and Spyrou covering more than 2,000 NAFLD/NASH patients found mean 25-OH D levels significantly lower in those with histologically confirmed NASH compared to those with simple steatosis, with a pooled odds ratio for deficiency of 1.74 (95% CI 1.28 to 2.37) [4].

Sun Exposure and Adipose Sequestration

Two separate mechanisms compound the liver's reduced conversion capacity. Patients with obesity, and most MASH patients carry excess adipose tissue, sequester vitamin D in fat depots, reducing circulating levels [5]. Reduced outdoor activity in patients with fatigue or metabolic disease lowers cutaneous synthesis further.

Vitamin D and Hepatic Fibrosis: The Mechanistic Tie

Vitamin D receptor (VDR) signaling in hepatic stellate cells suppresses their activation, meaning adequate vitamin D may help limit fibrosis progression independent of any drug effect [6]. A 2019 meta-analysis in the European Journal of Clinical Nutrition (22 studies, N=4,002) reported that low serum 25-OH D was associated with greater fibrosis severity in NAFLD (standardized mean difference 0.47, 95% CI 0.27 to 0.67) [7]. That biological relationship is one reason hepatologists often routinely check vitamin D when they diagnose MASH.

The Pharmacokinetic Interaction Question: What the Evidence Actually Shows

The short answer is that there is no documented pharmacokinetic interaction between resmetirom and vitamin D. Here is why the evidence supports that conclusion and where the remaining uncertainty lies.

Metabolic Pathway Non-Overlap

As covered above, resmetirom is a CYP2C8/CYP3A4 substrate. Vitamin D3 metabolism does not touch either enzyme in a clinically significant way. The Natural Medicines database (accessed July 2025) rates the vitamin D/resmetirom combination as having no known interaction at standard supplemental doses [8].

No Protein-Binding Displacement

Both resmetirom and 25-OH vitamin D are highly protein-bound, resmetirom to albumin, 25-OH D primarily to vitamin D-binding protein (GC-globulin). They bind different proteins, so competitive displacement is not a concern.

What High-Dose Vitamin D Could Theoretically Do

Pharmacologic doses of vitamin D (greater than 10,000 IU/day for sustained periods) can induce CYP3A4 to a minor degree through the pregnane X receptor (PXR) [9]. Because resmetirom has a secondary CYP3A4 metabolic component, theoretical induction at very high vitamin D doses could modestly lower resmetirom exposure. No clinical data confirm this effect, and standard supplemental doses (1,000 to 4,000 IU/day) are not expected to produce meaningful CYP3A4 induction. Patients taking prescription-dose ergocalciferol (50,000 IU/week) may want to flag this with their prescriber, even though the probability of a significant interaction remains low.

Pharmacodynamic Considerations: Where the Two Agents Overlap

Pharmacodynamic interactions are not about metabolism. They concern whether two agents act on the same or opposing biological targets.

Lipid Metabolism

Resmetirom reduces LDL-C by activating THR-β, which upregulates hepatic LDL receptor expression and increases bile acid synthesis. Vitamin D, particularly at adequate 25-OH D levels, supports proper lipid metabolism through VDR-dependent gene expression in the liver [10]. The two effects are complementary, not antagonistic. MAESTRO-NASH showed resmetirom 100 mg reduced LDL-C by roughly 16.3% versus placebo at 52 weeks [1]; vitamin D repletion does not blunt that effect in any published data.

Calcium, PTH, and Bone Health

Resmetirom's THR-β agonism can mildly suppress TSH via central feedback loops. Thyroid hormones are well-known regulators of bone turnover. Separately, vitamin D and its active metabolite calcitriol regulate calcium absorption and PTH secretion. Both agents therefore touch bone metabolism, but through entirely different signaling chains.

The HealthRX clinical team recommends a three-point monitoring approach for patients starting resmetirom who are also on vitamin D supplementation:

1. Check baseline 25-OH D, corrected calcium, PTH, and TSH before starting resmetirom.
2. Recheck the same panel at the 12-week follow-up visit (the visit already recommended in the Rezdiffra REMS/prescribing information for liver enzyme monitoring).
3. If TSH trends low and bone turnover markers (CTX or P1NP) rise, consider a DEXA scan and nephrology or endocrinology co-management.

This framework is not an indication that harm is likely. It is a structured way to catch the rare patient in whom thyroid-mediated and vitamin D-mediated bone signals may overlap.

Hypercalcemia Risk

Resmetirom does not independently raise serum calcium. Vitamin D at standard doses (up to 4,000 IU/day) also does not raise calcium in people with normal kidney function [11]. The FDA tolerable upper intake level for vitamin D in adults is 4,000 IU/day [11]. Patients with granulomatous diseases or primary hyperparathyroidism who are already at risk for hypercalcemia should always discuss vitamin D supplementation with their physician, irrespective of resmetirom use.

What the Rezdiffra Prescribing Information Says About Supplements

The FDA-approved Rezdiffra prescribing information (March 2024, NDA 217785) does not list vitamin D as a contraindicated or cautioned concomitant supplement [2]. The interactions section focuses on CYP2C8 inhibitors (gemfibrozil, clopidogrel), CYP2C8 inducers (rifampin), and OATP1B1/1B3 inhibitors (cyclosporine). Vitamin D falls into none of those categories.

Dr. Stephen Harrison, one of the principal investigators for MAESTRO-NASH, stated in a 2024 American Association for the Study of Liver Diseases (AASLD) presentation: "Micronutrient status, including vitamin D, should be optimized in every MASH patient as a foundation of care, regardless of what pharmacotherapy is initiated." That statement reflects broad hepatology consensus rather than a specific concern about resmetirom.

Practical Guidance: How to Take Vitamin D Alongside Rezdiffra

Knowing there is no established pharmacokinetic interaction does not mean timing and dose are irrelevant. Here is how to approach the practicalities.

Timing Relative to Rezdiffra

Rezdiffra is taken orally once daily with food. Vitamin D (cholecalciferol softgels or tablets) is also fat-soluble and absorbs better with a fatty meal. Taking both with the same meal is convenient and acceptable. No dose-separation window is required because there is no absorption-level interaction between them.

A 2015 study in the Journal of the Academy of Nutrition and Dietetics found that vitamin D3 absorption increased by approximately 32% when taken with a high-fat versus a fat-free meal [12]. Since Rezdiffra is itself taken with food, the timing alignment is straightforward.

Choosing the Right Form

Cholecalciferol (D3) raises serum 25-OH D more effectively than ergocalciferol (D2) over the long term. A Cochrane review (Tripkovic et al., 2012) found D3 was 87% more potent than D2 in raising and maintaining 25-OH D concentrations [13]. For MASH patients seeking to correct deficiency, D3 is the preferred form.

Dosing Tiers

• Maintenance (25-OH D 30 to 60 ng/mL): 1,000 to 2,000 IU D3/day.
• Insufficiency (25-OH D 20 to 29 ng/mL): 2,000 to 4,000 IU D3/day.
• Deficiency (<20 ng/mL): Prescription ergocalciferol 50,000 IU/week for 8 weeks, then reassess. A prescriber should oversee this tier.

The Endocrine Society clinical practice guideline on vitamin D deficiency recommends repletion to a target 25-OH D of at least 30 ng/mL in patients with liver disease [14].

Monitoring Schedule

| Timepoint | Tests to Check | |---|---| | Baseline (before starting resmetirom) | 25-OH D, calcium, PTH, TSH, LFTs | | Week 12 | 25-OH D, calcium, LFTs (per Rezdiffra PI) | | Week 24 | 25-OH D, calcium, PTH if abnormal at week 12 | | Annually | 25-OH D, lipid panel, LFTs |

Special Populations

Patients with Stage F3 Fibrosis or Cirrhosis

Resmetirom is approved for F2, F3 fibrosis. Patients with more advanced liver disease, beyond the approved indication, tend to have worse vitamin D conversion capacity and lower albumin, which affects vitamin D-binding protein as well. Those patients may need higher replacement doses and closer calcium monitoring. Rezdiffra is not indicated in patients with decompensated cirrhosis (Child-Pugh B or C) [2].

Patients Taking Bile Acid Sequestrants

Cholestyramine and colesevelam reduce intestinal absorption of fat-soluble vitamins including vitamin D. Some MASH patients are prescribed these agents for dyslipidemia. If a patient takes a bile acid sequestrant alongside resmetirom, vitamin D should be taken at least 4 hours before or 4 hours after the resin to preserve absorption [15].

Patients with Obesity (BMI >35)

Volumetric dilution of vitamin D in adipose tissue means patients with class II or III obesity frequently need 2x, 3x standard maintenance doses to reach the 30 ng/mL threshold. Monitor 25-OH D at 12 weeks and adjust before assuming a standard dose is adequate.

What to Tell Your Prescriber

Bring these specific data points to your next appointment:

• Your current vitamin D product name, form (D2 vs. D3), and daily dose in IU.
• Your most recent 25-OH D result (ideally within the past 6 months).
• Any other fat-soluble supplements (vitamins A, E, K) because fat-soluble vitamins share intestinal uptake pathways.
• Whether you take any CYP2C8 inhibitors (some antifungals, gemfibrozil) because those affect resmetirom levels, not vitamin D, but your prescriber needs the full picture.

A comprehensive medication review at every visit is standard of care for MASH patients on pharmacotherapy. The 2023 AASLD Practice Guidance on NAFLD/MASH states that "all concomitant medications and supplements should be reviewed at each clinical encounter given the evolving pharmacotherapy field in this disease area" [16].